Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation (Mild-MT)
Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation: A Multicenter Prospective Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Wenhuo Chen, MD
- Phone Number: +8613806906089
- Email: 13806906089@126.com
Study Contact Backup
- Name: Tingyu Yi, MD
- Phone Number: +8615859635985
- Email: siyuyufen@163.com
Study Locations
-
-
Fujian
-
Zhangzhou, Fujian, China, 363000
- Recruiting
- Zhangzhou Municipal Hospital
-
Contact:
- Tingyu Yi, MD
- Phone Number: 15859635985
- Email: siyuyufen@163.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730050
- Recruiting
- Gansu Provincial Hospital of Traditional Chinese Medicine
-
Contact:
- Ya Shao, MD
- Phone Number: 18919810265
- Email: shaoya20042001@126.com
-
-
Heilongjiang
-
Jiamusi, Heilongjiang, China, 154000
- Recruiting
- Jiamusi Central Hospital
-
Contact:
- Li-hua Xu, MD
- Phone Number: 13846178333
- Email: drxulihua@163.com
-
-
Jiangxi
-
Ganzhou, Jiangxi, China, 330000
- Recruiting
- Ganzhou People's Hospital
-
Contact:
- Guoyong Zeng, MD
- Phone Number: 13507079530
- Email: hsyygy@163.com
-
Nanchang, Jiangxi, China, 330006
- Recruiting
- The First Affiliated Hospital of Nanchang University
-
Contact:
- Xiaobing Li, MD
- Phone Number: 13970935284
- Email: lxb0203208@126.com
-
-
Jilin
-
Songyuan, Jilin, China, 138000
- Recruiting
- Songyuan Jilin Oilfield Hospital
-
Contact:
- Dongsheng Ju
- Phone Number: 13894158599
- Email: judongsheng_1981@163.com
-
-
Liaoling
-
Shenyang, Liaoling, China
- Recruiting
- Shenyang First People's Hospital
-
Contact:
- Yi Sui, MD
- Phone Number: 13998352587
- Email: tjyiia@hotmail.com
-
-
Zhejiang
-
Lishui, Zhejiang, China, 310000
- Recruiting
- Lishui Central Hospital
-
Contact:
- Xueli Cai
- Phone Number: 13967059836
- Email: mailto:xueli_cai_official@126.com
-
Taizhou, Zhejiang, China, 310000
- Recruiting
- Taizhou First People's Hospital
-
Contact:
- Chenghua Xu
- Phone Number: 15857655838
- Email: samuel5098@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-80 years old;
- Symptoms onset or last known well to randomization is within 24 hours.
- Clinical diagnosis of acute ischemic stroke due to anterior circulation intracranial large vessel occlusion (LVO) (including intracranial internal carotid artery [ICA], middle cerebral artery [MCA] M1 segment, MCA M2 segment, with or without ipsilateral extracranial ICA occlusion) confirmed on Computerized tomography angiography (CTA) or Magnetic resonance imaging angiography (MRA) ;
- Baseline NIHSS score <6 before randomization (including cases with NIHSS ≥6 at onset but improves before randomization);
- ASPECTS score ≥6 based on Non-contrast CT (NCCT) before randomization;
Exclusion Criteria:
- Premorbid Rankin Scale (mRS) score ≥ 1;
- Known allergy to iodine, heparin, anaesthesia, or other definite contraindication to receiving endovascular treatment (EVT) procedure;
- Patient has severe or fatal co-morbidities that could interfere with outcome assessments and follow-up (such as malignant tumor, severe heart failure, or renal failure, or life expectancy less than 6 months);
- Poorly controlled hypertension (systolic blood pressure >220 mmHg or diastolic blood pressure >120 mmHg);
- Baseline blood glucose <50mg/dL (2.78 mmol/L) or >400mg/dL (22.20 mmol/L);
- Known bleeding tendencies, including but not limited to platelet count <100×109/L; received heparin treatment within 48 hours with an activated partial thromboplastin time (APTT) ≥35s; recent oral anticoagulant therapy with international normalized ratio (INR) >3; Note: Patients without a history of coagulation abnormalities or without suspicion of coagulation abnormalities do not need to wait for laboratory test results before enrollment;
- Seizures at stroke onset or during the course, hard to accurately judge the baseline NIHSS score;
- Female who is known to be pregnant, lactation, or tested positive for pregnancy at time of admission;
- Currently participating in another investigational drug study or medical device treatments that may interfere with the results of this study;
- Evidence of intracranial hemorrhage on CT/MRI, including cerebral parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural/extradural hemorrhage;
- Significant midline displacement, hernia of brain, or ventricular mass effect with midline displacement confirmed on CT/MRI;
- Anticipated impossibility to complete endovascular treatment, such as vascular tortuosity, severe vascular wall calcification, etc.;
- Aortic dissection;
- Multiple intracranial large vessel occlusions confirmed by CTA or MRA, unable to clearly identify the symptomatic vessel, such as bilateral MCA occlusions or occlusions involving both the MCA and basilar artery;
- Suspected or confirmed occluded artery is non-acute occlusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental Group
The operator will choose the optimal endovascular treatment strategy and device based on the patient's condition and clinical experience.
This may include, but is not limited to, stent retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, etc.
The endovascular treatment plan and relevant time points will be accurately recorded.
The patient will receive the best medical treatment according to current local clinical research standards during and after the procedure.
|
Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines.
This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on.
The EVT regimen and relevant time points will be accurately recorded.
The patient will receive the best medical treatment according to the local guidelines.
Other Names:
|
|
No Intervention: Control Group
Patients will receive the best medical treatment according to local clinical research standards, including antiplatelet agents, anticoagulants, thrombolysis, etc., excluding any endovascular treatment.
In the event of disease progression defined as neurological deterioration leading to an increase in NIHSS ≥4 points and excluding non-stroke factors within 24 hours, remedial endovascular treatment may be taken, including but not limited to stent retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, etc.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of excellent outcome
Time Frame: 90±7 days
|
mRS score 0-1
|
90±7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of good outcome
Time Frame: 90±7 days
|
mRS score 0-2
|
90±7 days
|
|
mRS shift
Time Frame: 90±7 days
|
distribution of mRS scores
|
90±7 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of symptomatic intracranial hemorrhage
Time Frame: Within 48 hours
|
According to the Heidelberg criteria
|
Within 48 hours
|
|
Rate of early neurological deterioration
Time Frame: Within 7 days
|
An increase in NIHSS≥4 or an increase of ≥2 in any individual item
|
Within 7 days
|
|
Mortality
Time Frame: 90±7 days
|
Death
|
90±7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tingyu Yi, MD, Zhangzhou Affiliated Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Mild-MT registry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.